Resoundant

Executive Summary

Resoundant is a Rochester, Minnesota-based medical technology company that commercializes Magnetic Resonance Elastography (MRE), a noninvasive imaging technique that measures tissue stiffness. The company’s core product is an FDA-cleared method for staging liver fibrosis, offering an alternative to invasive liver biopsies. Founded in 2010 as a spin-out from Mayo Clinic, Resoundant aims to transform diagnostic imaging by providing quantitative biomarkers for liver disease and potentially other fibrotic conditions. The company has secured FDA clearance for liver fibrosis staging and is actively pursuing broader clinical adoption and new applications for MRE technology. Resoundant’s MRE technology addresses a significant unmet need in noninvasive liver disease monitoring, with the potential to reduce the number of biopsies and improve patient management. The company’s future growth depends on expanding its platform into additional organs (e.g., kidney, pancreas) and securing partnerships with major imaging providers and pharmaceutical companies for clinical trials. Resoundant is well-positioned to capitalize on the growing demand for noninvasive diagnostics, though it faces competition from other imaging modalities and biomarker-based tests. The company’s strong intellectual property portfolio and Mayo Clinic affiliation provide a competitive edge as it scales commercialization.

Upcoming Catalysts (preview)

• Q4 2026FDA clearance for kidney fibrosis imaging indication60% success
• Q2 2027Key partnership with a major hospital network for MRE adoption70% success
• Q1 2027Publication of pivotal clinical study on MRE for NASH (non-alcoholic steatohepatitis) fibrosis staging75% success